Open AccessProspective assessment of 18F-FDG PET/CT in detection of recurrent ovarian cancer
Author(s) -
Ghada K. Gouhar,
Soha Siam,
Somayya M. Sadek,
Reda A. Ahmed
Publication year - 2013
Publication title -
the egyptian journal of radiology and nuclear medicine /the egyptian journal of radiology and nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 13
eISSN - 2090-4762
pISSN - 0378-603X
DOI - 10.1016/j.ejrnm.2013.08.005
Subject(s) - medicine , radiology , positron emission tomography , ovarian cancer , malignancy , ovarian carcinoma , radiological weapon , metastasis , stage (stratigraphy) , nuclear medicine , cancer , paleontology , biology
AbstractObjectiveTo assess the use of positron emission tomography (PET)/computed tomography (CT) in patients with suspected ovarian cancer recurrence and describe the distribution of metastasis.Patients and methodsThis study included (39) patients suspected to have recurrent ovarian malignancy. This suspicion was either clinically, radiologically or due to raised CA-125 levels. All patients underwent 18F-FDG PET/CT, surgery was performed within 8weeks of imaging studies. Surgical and/or histopathological examinations were available in 31 patients, and clinical, radiological and CA 125 serum level follow up in 8 patients.ResultsThe overall lesion-based sensitivity, specificity, and accuracy of PET/CT for revealing recurrent ovarian carcinoma were 90%, 98% and 97%, respectively. The patient – based sensitivity, specificity, and accuracy of PET/CT were 97%, 75% and 95%, respectively.Conclusion18F-FDG PET/CT is a useful tool for evaluating the recurrence of ovarian cancer after first-line therapy in patients with a high risk of relapse, equivocal radiologic findings, increased or normal levels of serum CA-125. It can more accurately diagnose and localize recurrence, hence decreasing the rate of second look surgery and changing treatment plan